Business
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
Webcast to be Held on Friday, October 20, 2023 at 8:00 a.m. ET WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\nWebcast to be Held on Friday, October 20, 2023 at 8:00 a.m. ET\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.\n\n\nThe event will feature presentations and discussions with:\n\n\n\nJamie Fergie, MD, FAAP, FIDSA, FSHEA – Medical Director, Global Institute for Hispanic Health, Professor of Pediatrics, Texas A&M University and Director, Infectious Diseases, Driscoll Children’s Hospital\n\n\n\nTom Wilkinson, MA (Cantab), MBBS, PhD, FRCP, FERS – Professor of Respiratory Medicine and Associate Dean, University of Southampton and Faculty of Medicine, Southampton General Hospital\n\n\n\nThe event will be led by Jay R. Luly, PhD, President and Chief Executive Officer of Enanta, who will be joined by Scott T. Rottinghaus, MD, Senior Vice President and Chief Medical Officer, and John DeVincenzo, MD, Vice President of Translational Virology.\n\n\nComplete speaker biographies can be found on the Event registration page here.\n\n\nEvent details are as follows:\n\n\nRespiratory Syncytial Virus: The Evolving Treatment Landscape\nDate and Time: October 20, 2023 at 8:00 a.m. ET\nWebcast Link: Register\n\n\nA webcast of the event will be available on the investor relations page of the Enanta Pharmaceuticals website at https://ir.enanta.com/events-presentations. A replay of the webcast will be archived on Enanta’s website for at least 30 days following the presentation.\n\n\nAbout Enanta Pharmaceuticals, Inc.\n\n\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).\n\n\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curi...